Abbott Laboratories EPS beats by $0.15, beats on revenue

Jul. 22, 2021 7:16 AM ETAbbott Laboratories (ABT)ABTBy: Gaurav Batavia, SA News Editor13 Comments
  • Abbott Laboratories (NYSE:ABT): Q2 Non-GAAP EPS of $1.17 beats by $0.15; GAAP EPS of $0.66 in-line.
  • Revenue of $10.22B (+39.4% Y/Y) beats by $550M.
  • FY21 Guidance: Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95. Abbott forecasts specified items for the full-year 2021 of $1.55 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align its COVID-19 testing-related business with current and projected demand, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for full-year 2021 ($4.36 consensus).
  • Press Release

Recommended For You

Comments (13)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.